Each ml contains: Timolol (as Timolol Maleate) 5mg, Benzalkonium Chloride 0.01% w/v (as preservative).
In sterile aqueous buffered vehicle.
Pharmacology: Iotim ED when applied topically in the eye has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma.
The exact mechanism by which timolol reduces IOP has not been clearly defined. Fluorophotometric studies suggest that the reduced aqueous humor formation is the predominant effect.
Pharmacodynamics: Timolol is a competitive antagonist at both beta 1 and beta 2 adrenoceptors: it is therefore a non-selective beta blocking drug.
Timolol combines reversibly with the beta-adrenergic receptor, and this inhibits the usual biologic response that would occur with stimulation of that receptor. This specific competitive atagonism blocks stimulation of the beta-adrenergic stimulating activity, whether these originate from an endogenous or exogenous source.
Pharmacokinetics: The onset of reduction in intraocular pressure following administration of Timolol can usually be detected within one half hours after a single dose; maximum effect usually occurs after one to two hours.
Iotim ED is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
Instill one drop in the affected eye(s) twice daily or as directed by the physician.
Transfer from other agents: When another topical beta blocking agent is being used, discontinue its use after a full day of therapy and start treatment with lotim the next day with one drop of 0.25% lotim ED in each affected eye twice a day. The dosage may be increased to one drop of 0.5% solution in each affected eye twice a day if the response is not adequate.
When transferring a patient from a single anti glaucoma agent other than a topical beta blocking agent, continue the agent and add one drop of 0.25% lotim ED in each affected eye twice a day. On the following day, discontinue the previous agent completely, and continue with lotim ED. If a higher dosage of lotim ED is required, substitute one drop of 0.5% solution in each affected eye twice a day.
Route of administration: For Ophthalmic Use.
Symptoms and Treatment of Overdosage: There have been reports of inadvertent overdosage of lotim ED resulting in systemic Beta-adrenergic blocking effects such as dizziness, headache, shortness of breath, bradycardia, bronchospasm and cardiac arrest.
Over dosage has been reported with Timolol Maleate Tablets. A 30 years old female ingested 650 mg of Timolol (maximum recommended oral daily dose is 60 mg) has experienced second and third degree heart block. The patient recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate and borderline first degree heart block. The oral LD 50 of the drug is 1190 and 900 mg / kg in female mice and female rats respectively.
An in vitro hemodialysis study, using 14C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.
The most common signs and symptoms to be expected with overdosage with administration of a systemic beta-adrenergic receptor blocking agent are symptomatic bradycardia, hypotension, bronchospasm and acute cardiac failure. The following therapeutic measures should be considered.
Gastric Lavage: If ingested.
Symptomatic bradycardia: Use atropine sulfate intravenously in a dosage of 0.25mg to 2mg to induce vagal blockade.
If bradycardia persists, intravenous isoproterenol hydrochloride should be administered cautiously. In refractory cases, the use of a transvenous cardiac pacemaker may be considered.
Hypotension: Use sympathomimetic pressor drug therapy such as dopamine, dobutamine or levarterenol. In refractory cases, the use of glucagon hydrochloride has been reported to be useful.
Bronchospasm: Use of isoproterenol hydrochloride. Additional therapy with aminophylline may be considered.
Acute cardiac failure: Conventional therapy with digitalis, diuretics and oxygen should be instituted immediately. In refractory cases, the use of intravenous aminophylline is suggested. This may be followed if necessary by glucagons hydrochloride which has been reported to be useful.
Heart block (second or third degree): Use isoproterenol hydrochloride or a transvenous cardiac pacemaker.
Timolol is contraindicated in patients with bronchial asthma, or a history of bronchial asthma or severe chronic obstructive pulmonary disease, sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of the product.
Precautions: Iotim ED should be used during pregnancy and lactation only if the potential benefit justifies the potential risk to the fetus. Because of the potential for serious adverse reactions from Iotim ED in nursing infants, a decision should be taken whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug for the mother. Safety and effectiveness in pediatric patients have not been established.
Warnings: As with many topically applied ophthalmic drugs, this drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adernergic blocking agents may occur with topical administration. For e.g. severe respiratory reactions and cardiac reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure have been reported following systemic or ophthalmic administration of Timolol.
Cardiac Failure: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardiac contractivity, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
In patients without a cardiac failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure.
Patients with chronic obstructive pulmonary disease (e.g. bronchitis, emphysema) of mild and moderate severity, bronchospastic disease, or a history of bronchospastic disease in which Timolol is contraindicated should, in general, not receive beta-blockers including lotim ED. Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes). Beta-adrenergic blocking agents may mask certain clinical signs of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.
Local irritation is the only commonly observed adverse reaction. Bronchoconstriction is reported in elderly patients with pulmonary obstructive disease.
Iotim ED is generally well tolerated following topical application to the eye.
Signs and symptoms of ocular irritation, including burning & stinging sensation, conjunctivitis, blepharitis, keratitis and blepharoptosis have been reported occassionally in patients receiving topical timolol therapy. Visual disturbances including refractive changes (resulting from withdrawal of miotic therapy in some patients) have been infrequently associated with timolol therapy. Decreased corneal sensitivity, diplopia and ptosis have also occurred. Aggravation or precipitation of certain cardiovascular pulmonary and other disorders, presumably related to effects of systemic beta-adrenergic blockade, may occur during therapy with topical timolol and may include bradycardia, arrhythmia, congestive heart failure, hypotension, syncope, heart block, cerebrovascular accident, cerebral ischemia, palpitation, dyspnea, nasal congestion, cough bronchospasm (mainly in patients with pre-existing bronchospastic disease) and respiratory failure. Headache, depression, dizziness, paresthesia, asthenia, diarrhoea and nausea have also been reported in patients receiving topical timolol therapy.
Although Timolol used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with Timolol and epinephrine has been reported occasionally. Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marketed bradycardia, which may produce vertigo, syncope or postural hypotension.The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. Patients who are receiving beta adrenergic blocking agents orally and lotim Eye Drops should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta adrenergic blocking agents is not recommended.
Store below 30°C & protect from light.
Use the solution within one month after opening the vial.
Expiry date 24 months from the manufactured date.
S01ED01 - timolol ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
Eye drops 0.5% w/v (sterile clear colourless solution) x 5 mL.